老年肺结核的诊治现状与进展

doi:10.3969/j.issn.1000-6621.2015.05.013

摘要/Abstract

Key words: Tuberculosis, pulmonary/ diagnosis , Tuberculosis, pulmonary/ therapy, Aged

吴妍李琦. 老年肺结核的诊治现状与进展[J]. 中国防痨杂志, 2015, 37(9): 975-978. doi: 10.3969/j.issn.1000-6621.2015.05.013

WU Yan, LI Qi. The status and progress of diagnosis and treatment for elderly patients with tuberculosis[J]. Chinese Journal of Antituberculosis, 2015, 37(9): 975-978. doi: 10.3969/j.issn.1000-6621.2015.05.013

参考文献

[1] World Health Organization. Global tuberculosis report 2014[M]. Geneva：World Health Organization, 2014: 1-171.
[2] 中华人民共和国国家统计局. 2010年第六次全国人口普查主要数据公报(第1号)[EB/OL] (2011-04-28).[2015-07-16] http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/201104/t20110428_30327.html,
[3] 全国第五次结核病流行病学抽样调查技术指导组，全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志，2012, 34（8）：485-508.
[4] 卢德友. 1784例老年人肺结核临床特点分析. 中华老年医学杂志，2005,24(7):530-531.
[5] 马玙，黄学锐. 老年人肺结核的临床特点及诊治对策. 中华老年医学杂志, 2005,24（6）：406-409.
[6] 徐牧. 老年人肺结核125例临床分析.中华老年医学杂志，2009,28（5）：412-413.
[7] He GX, Zhao YL, Jiang GL, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis, 2008, 8(11):166.
[8] 郝晓军，姚岚，孙华，等. 老年耐多药肺结核临床特征及转归分析. 中华结核和呼吸杂志，2014,37（3）：188-191.
[9] Guzmán-Pérez C, Vargas M. Does aging modify pulmonary tuberculosis? A meta-analytical review. Chest, 1999, 116(4): 961-967.
[10] 王仲元，苏锐，安慧茹，等. 老年肺结核643例的临床特点. 中华结核和呼吸杂志，2012,35（3）：213-214.
[11] Inghammar M, Ekbom A, Engstrom G, et al. COPD and the Risk of Tuberculosis- A Population-Based Cohort Study. PLoS One, 2010, 5(4): e10138.
[12] Lee JH, Han DH, Song JW, et al. Diagnostic and Therapeutic Problems of Pulmonary Tuberculosis in Elderly Patients. J Korean Med Sci, 2005, 20(5): 784-789.
[13] 苏慧勇，张国丽. 118例老年肺结核的X线特点. 临床肺科杂志，2011,16(2)：286-287.
[14] Wolf AJ, Desvignes L, Linas B, et al. Intiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med, 2008, 205(1): 105-115.
[15] Orme IM, Lee BY, Appelberg R, et al. T cell response in acquired protective immunity to mycobacterium tuberculosis infection. Bull Int Union Tuberc Lung Dis, 1991, 66(1): 7-13.
[16] Korzeniewska-Kosela M, Krysl J, Muller N, et al. Tuberculosis in young adults and the elderly. A prospective comparison study. CHEST, 1994, 106(1):28-32.
[17] Tuberculosis Surveillance Center. Tuberculosis annual report 2010. Kekkaku. 2012,87(9):585-589.
[18] Oshi DC, Oshi SN, Alobu I, et al. Profile and Treatment Outcomes of Tuberculosis in the Elderly in Southeastern Nigeria, 2011-2012. PLoS One, 2014, 9(11): e11910.
[19] Velayutham BR, Nair D, Chandrasekaran V, et al. Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India. PLoS One, 2014, 9(3): e88045.
[20] Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med, 2003, 167(11):1472-1477.
[21] Meier Y, Cavallaro M, Roos M. et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol, 2005, 61(2):135-143.
[22] 夏愔愔，詹思延. 国内抗结核药物不良反应发生率的综合分析. 中华结核和呼吸杂志，2007,30（6）：419-423.
[23] 国务院办公厅.全国结核病防治规划（2011-2015年）的通知[EB/OL]. (2011-12-06)[2011-11-17].http://www.gov.cn/zwgk/2011-12/06/content_2012869.html.
[24] Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and electiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet, 2011, 377(9776):1495-1505.
[25] Hu PL, Bai LQ, Liu FP, et al. Evaluation of the Xpert MTB/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level laboratories in Hunan province, China. Chin Med J (Engl), 2014, 127(21): 3744-3750.
[26] Yeh JJ, Chen SC, Chen CR, et al. A high-resolution computed tomography-based scoring system to differentiate the most infectious active pulmonary tuberculosis from community-acquired pneumonia in elderly and non-elderly patients. Eur Radiol, 2014, 24(10): 2372-2384.
[27] Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep, 2010, 59(RR-5)：1-25.
[28] Ruiz-Manzano J, Blanquer R, Calpe JL, et al. Diagnosis and treatment of tuberculosis. Arch Bronconeumol, 2008, 44(10):551–566.
[29] 中华医学会结核病学分会. γ-干扰素释放试验在中国应用的建议. 中华结核和呼吸杂志，2014，,37（10）：744-747.
[30] 万荣，李明武，赖明红，等. 结核感染T细胞斑点试验在老年肺结核中的诊断价值. 中国防痨杂志，2015,37(4): 348-352.
[31] Le Hang NT, Lien LT, Kobayashi N, et al. Analysis of factors lowering sensitivity of interferon-γ release assay for tuberculosis. PLoS One, 2011,6(8): e23806.
[32] 中华医学会结核病学分会. 肺结核诊断和治疗指南. 中华结核和呼吸杂志，2001,24（2）：70-74.
[33] World Health Organization. Treatment of tuberculosis guidelines fourth edition. Geneva: World Health Organization, 2010: 1-147.
[34] 高微微. 老年肺结核患者治疗问题探讨. 中华结核和呼吸杂志，2014,37（10）：732-733.
[35] 赵开顺，徐惠明，屠春林. 上海市嘉定区75例老年肺结核个体化治疗的临床分析. 中国防痨杂志, 2013,35(7): 548-550.
[36] 李进升，黄秋霞，余少英，等. 含利福喷丁或利福平联合化疗方案对老年肺结核患者药物性肝损伤的临床比较. 中国防痨杂志, 2014,36(6): 514-516.
[37] World Health Organization. Guideline: Nutritional care and support for patients with tuberculosis. Geneva : World Health Organization, 2013: 1-54.
[38] 谭守勇，吴碧彤，林兆原，等. 免疫干预治疗对老年肺结核细胞免疫及低蛋白血症影响. 中国防痨杂志. 2011,33（4）：254-256.